

This is a repository copy of *The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/114420/>

Version: Accepted Version

---

**Article:**

Nappo, G, Handle, F, Santer, F R et al. (7 more authors) (2017) The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. *Oncogenesis*. e342. pp. 1-12. ISSN: 2157-9024

<https://doi.org/10.1038/oncsis.2017.23>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

**The Immunosuppressive Cytokine Interleukin-4 Increases the Clonogenic Potential of Prostate Stem-Like Cells by Activation of STAT6 Signalling**

**Giovanna Nappo<sup>1,2</sup>, Florian Handle<sup>3</sup>, Frédéric R. Santer<sup>3</sup>, Rhiannon V. McNeil<sup>5</sup>, Robert I. Seed<sup>1</sup>, Anne T. Collins<sup>1</sup>, Giovanni Morrone<sup>2</sup>, Zoran Culig<sup>3\*</sup>, Norman J. Maitland<sup>1,4\*</sup>, and Holger H. H. Erb<sup>1,6\*</sup>**

\*Joint senior authors

<sup>1</sup> The Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, YO10 5DD, UK

<sup>2</sup> Laboratory of Molecular Haematopoiesis and Stem Cell Biology, Department of Experimental and Clinical Medicine, Magna Græcia University, 88100 Catanzaro, Italy

<sup>3</sup> Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria

<sup>4</sup> Hull York Medical School, University of Hull, Hull, East Yorkshire, HU6 7RX, UK

<sup>5</sup> Jack Birch Unit for Molecular Carcinogenesis, University of York, York YO10 5DD, United Kingdom

<sup>6</sup> Urologisches Labor, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, 55130 Mainz, Germany

**Running Title:** IL-4 affects prostate tumour-initiating cells

**Grant Support**

This work was funded by PRO-NEST Marie-Curie Grant (238278 to ZC), Forschungsfoerderung der Oesterreichischen Krebshilfe Tirol 2012 (to HHHE), and the Austrian Science Fund FWF (P26799 to FRS). Further support was provided by Charity Soul and YCR (Y257PA to NM).

**Contact Information:**

Dipl.-Biol. Holger Erb, PhD

Urologisches Labor, Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsmedizin der Johannes Gutenberg-Universität, 55130 Mainz, Germany

Email: holger.erb@unimedizin-mainz.de

Tel: +49 (0) 1904 328707

Fax: +49 (0) 1904 328710

**Abstract**

Interleukin-4 plays a critical role in the regulation of immune responses and has been detected at high levels in the tumour microenvironment of cancer patients, where concentrations correlate with the grade of malignancy. In prostate cancer, interleukin-4 has been associated with activation of the androgen receptor, increased proliferation, and activation of survival pathways, such as Akt and NF- $\kappa$ B. However, its role in therapy resistance has not yet been determined. Here we investigate the influence of interleukin-4 on primary epithelial cells from prostate cancer patients. Our data demonstrate an increase in the clonogenic potential of these cells when cultured in the presence of interleukin-4. Additionally, a Phospho-Kinase Array revealed that, in contrast to previously published work, STAT6 is the only signalling molecule activated after interleukin-4 treatment. Using the specific STAT6 inhibitor, AS1517499 we could confirm the role of STAT6 in increasing colony-forming frequency. However, clonogenic recovery assays revealed that interleukin-4 does not rescue the effects of either irradiation or docetaxel treatment. We therefore propose that although the interleukin-4 /STAT6 axis does not appear to be involved in therapy resistance, it does play a crucial role in the colony forming abilities of the basal cell population in prostate cancer. IL-4 may therefore contribute to disease relapse by providing a niche that is favourable for the clonogenic growth of prostate cancer stem cells.

**Keywords:** Cancer Stem Cells, Irradiation, Docetaxel, STAT6, AS1517499, Cytokines

## Introduction

Prostate Cancer (PCa) is one of the most frequent malignancies in males (1). Treatment is strongly dependent on tumour stage, patient age, overall patient health and tumour risk assessment (2-4). The most commonly used treatment options for PCa are radical prostatectomy, radiation therapy, multiple endocrine therapies, and chemotherapy with docetaxel. Although most PCa patients respond initially to androgen deprivation treatment, the cancer inevitably recurs and progresses to highly aggressive castration resistant PCa (CRPC), for which only palliative therapeutic options exist (3, 5). However, the exact mechanism behind the development of CRPC is still unclear. One possible reason for this progression is that currently used therapies have only been designed to target, androgen receptor(AR)-positive luminal cells in the cancer (5). However, several studies have demonstrated that a small population of primitive cells, with a basal phenotype (characterized by AR<sup>-</sup>, CD49f<sup>+</sup>, CD44<sup>+</sup>, CKs 5/14<sup>+</sup>, and p63<sup>+</sup> markers) exist within the tumour, and have the capacity to evade current therapies (6-8). These rare cells (<1%) have been shown to possess a higher regenerative potential and express tumour markers (including AMACR and theTMPRSS2-ERG fusion gene) (9-11). Similar to benign prostate tissue, the basal cells (CD44<sup>+</sup>/CD49f<sup>+</sup>) from malignant areas, can further be subgrouped by high expression of  $\alpha 2\beta 1$  integrin complex (CD49b) which results in a rapid adhesion to collagen (12). The basal compartment can also be further fractionated into stem cells (SC, CD49b<sup>high</sup>/CD133<sup>+</sup>), the highly proliferative transit-amplifying cells (TA, CD49b<sup>high</sup>/CD133<sup>-</sup>) and committed basal cells (CB, CD49b<sup>low</sup>/CD133<sup>-</sup>) (5, 10). CB cells have also been reported in several studies as intermediate cells, and harbour luminal and basal markers, such as cytokeratins 5, 14 and 18 (5, 10). Interestingly, SC isolated from malignant areas (i.e. cancer stem cells, CSC) are highly invasive, have a shorter population doubling time and a distinct mRNA and miRNA profile compared to normal SC, and in addition can form tumours in mice(10, 11, 13).

Recent clinical studies have demonstrated that inflammation is not only linked to the development of cancer, but is also an indicator of poor prognosis (8, 14). Chronic inflammation has been associated with the production of a variety of cytokines by inflammatory cells, including interleukin (IL)-1, IL-6, and IL-4 (15). In addition to the action on immune cells, cytokines modulate the different cells types within the tumour microenvironment, and are able to induce cell transformation (15). For example, increased IL-6 levels have been observed in PCa tissues, and are suggested to influence growth and survival pathways (16). IL-6 expression levels in prostate tissue also (i) correlate with Gleason score and biochemical recurrence, (ii) influence tumour initiation, and (iii) affect clonogenic recovery after docetaxel treatment of PCa stem-like cells (16-18).

IL-4 is a multifunctional cytokine that plays with a critical role in the regulation of immune responses (19). Cytokine binding to the IL4R $\alpha$  subunit results in the activation of mediators of cell growth, resistance to apoptosis, gene activation and differentiation (19). The activated genes include AKT, p44/42 MAPK, NF- $\kappa$ B, and the JAK/STAT6 pathways, which represents the main mediator of IL-4 signalling in immune cells (19). Elevated levels of IL-4 (normally produced by tumour-infiltrating lymphocytes) have been documented in patients with progressive PCa (20-22), and *in vitro* studies using PCa cell lines have demonstrated that IL-4 activates NF- $\kappa$ B and AR in a ligand-independent manner (23). Treatment of androgen-sensitive LNCaP cells with IL-4 increased the expression of the co-activators CBP/p300 and their histone acetyltransferase activity (15, 24). Overexpression of IL-4 resulted in increased proliferation of LNCaP and 22Rv1 cell lines (25), whilst IL-4 treatment also induced the proliferation of the AR-negative PC3 cells under nutrient-depletion stress (26).

In this study, we investigated the physiological and molecular effects of the pleiotropic cytokine IL-4 on primary basal prostate cells, isolated from benign and malignant prostate biopsies. By simulating an IL-4 containing microenvironment (using IL-4 secreting feeder cells), we determined the effect of IL-4 on primary basal cell fate, cell mortality, cell invasion, and whether IL4 signalling is involved in therapy resistance.

## Results

### IL-4R $\alpha$ expression in primary prostate epithelial cells

IL-4 acts by binding to a heterodimeric receptor complex, composed of the IL4R alpha-chain (IL4R $\alpha$ ) and the common gamma-chain shared by several IL receptors (27). To evaluate IL4R $\alpha$  expression patterns in benign and malignant prostate tissue, we investigated expression of IL4R $\alpha$  in a tissue microarray (TMA) containing both malignant and adjacent benign areas from 36 PCa patients (Figure 1A). The TMA showed that IL4R $\alpha$  is mainly expressed in luminal cells and significantly elevated in cancerous compared to adjacent benign areas (Figure 1B). The bulk of prostate adenocarcinomas consist of luminal cancer cells, precluding analysis of the IL4R $\alpha$  expression levels in rare cell populations such as the basal cell compartment in malignant areas (12, 28). Due to these technical limitations, the detection of rare basal cell populations in human tissue by immunohistochemical methods is highly challenging. To overcome these limitations we made use of primary cell cultures from benign prostate hyperplasia (BPH) and PCa tissues specimens to amplify the number of basal epithelial cells. In contrast to the findings from the TMA (Figure 1A-B) IL4R $\alpha$  mRNA (Figure 1C) and protein levels (Figure 1D) were not significantly different between benign and cancerous CD44<sup>+</sup>/CD49f<sup>+</sup> basal cells, which both showed comparable expression levels to PC3 cells. Surprisingly, in view of the TMA data, LNCaP cells expressed only minimal levels of IL4R $\alpha$  (Figure 1C-D). To investigate IL4R $\alpha$  expression in the individual cell subpopulations, we separated SC, TA, and CB according to their surface markers, as previously described (12, 27, 28). The functional isolation of SC, TA, and CB subpopulations (based on their clonogenic potential) was confirmed (Supplementary Figure 1A), and qRT-PCR analysis of the SC, TA and CB subpopulations revealed that receptor expression was significantly increased in cancer (C)SC subpopulation and CTA within the basal cell population compared with their benign counterparts (Figure 1E). We were unable to stratify the clonogenicity of the basal populations or IL4R $\alpha$  expression according to expression of another common prostate (basal) stem cell marker CD49f (8) which marked all basal cells under these serum free culture conditions (Supplementary Figure 1B) (8).

### IL-4 increases the clonogenic potential of primary PCa cells

To simulate an IL-4-containing microenvironment, a human IL-4 cDNA construct was inserted into murine STO cells by lentiviral transduction. IL-4 expression and bioavailability as a secreted protein were confirmed by qRT-PCR and ELISA (Supplementary Figure 2A+B). The newly generated STO cell lines, STO-GUS (control cell line) and STO-IL4 (IL-4 secreting cell line) were used as feeder layers for the primary prostate epithelial cultures in subsequent experiments in order to investigate the influence of IL-4 on clonogenic

potential. After 15 days of culture, benign primary cells, co-cultured with STO-IL4 cells, showed a minor increase in CFE, compared to cells co-cultured with STO-GUS (Figure 2A, Supplementary Figure 3A). In contrast, primary PCa cells showed a significantly (~3-fold) higher clonogenic potential in response to STO-IL4 (Figure 2B, Supplementary Figure 3B). Similar effects were seen when PCa cells were co-cultured with untransduced STO cells in the presence of 5ng/ml recombinant IL-4 (Supplementary Figure 3C). To investigate whether the presence of IL-4 affects the proliferative ability of primary cells, colony growth was tracked over time. Surprisingly, there was no significant difference between the size of colonies in STO-GUS or STO-IL4 co-cultured cells, or between cancer and benign cells (Figure 2C-D). Similar results were observed with cell lines and primary cells treated with 5ng/ml exogenous IL-4 for 7 days (Supplementary Figure 3D-H). Moreover, [<sup>3</sup>H] Thymidine incorporation assays (Supplementary Figure 3I-L) and MTT assays (Supplementary Figure 3M-P) of commonly used PCa cell lines treated with a concentration range of IL-4 confirmed that IL-4 is not able to affect cellular proliferation rate and viability, respectively. To further corroborate whether IL-4 expedites colony formation, the development of colonies was scored over time. After 6 days there was a significant increase in colony number in primary PCa cells co-cultured with STO-IL4 compared to controls (STO-GUS) (Figure 2E). Thus, IL-4 is able to increase CFE of primary PCa cells but once colonies have formed, IL-4 is unable to regulate the expansion of these colonies.

To investigate whether CFE of PCa cells is dependent on the concentration of IL-4, primary cancer cells were co-cultured with STO-IL4/STO-GUS cells at different ratios (Figure 2F). For these experiments STO-IL4 cells were diluted with STO-GUS cells to a maximum ratio of 1:10,000. The IL-4 concentrations of the supernatants were determined after 2 days by ELISA and showed a concentration range from 0.004 ng/ml to 32 ng/ml (Supplementary Figure 4A). The results demonstrated that the number of colonies correlated (Supplementary Figure 4B+C,  $R^2 = 0.867$ ,  $p = 0.021$ ) with the concentration of IL-4 in the supernatant suggesting that the clonogenic potential of primary PCa cells is increased in a dose-dependent manner by IL-4. Since IL-4 effects on benign cells were absent, subsequent experiments were performed with malignant cells only.

#### **IL-4 does not influence the migration or invasive potential of primary PCa cells**

In order to determine whether IL-4 influences the chemotaxis of primary PCa cells, migration (Figure 3A) and invasion assays (Figure 3B) were performed with Boyden chambers in the presence of STO-IL4 and STO-GUS acting as chemoattractants. Media with no supplements/chemoattractants were used as a negative control and medium supplemented with 30% FCS was used as a positive control (13). STO cells in the

absence of FCS had a similar effect on migration and invasion as 30% FCS. However, we were unable to see any statistically significant effects on migration and invasion of primary PCa cells when STO-IL4 was used as a chemoattractant. Noteworthy, this type of assay does not discriminate between the different subpopulations of primary PCa cells. We can therefore not exclude that SC niches do not need to secrete IL-4 in order to attract SC or CSC.

#### **IL-4 signaling does not affect the sensitivity of primary PCa cells to irradiation or docetaxel**

Multiple cytokines, such as IL-6, IL-8, and IL-4, have been shown to be expressed at higher levels after cancer treatment (e.g. radiation and chemotherapy (docetaxel), and may play a crucial role in resistance mechanisms (15, 20, 29). In order to verify whether IL-4 may influence the recovery potential of primary cancer cells after irradiation, clonogenic recovery assays were performed after cells were exposed to increasing doses of  $\gamma$ -irradiation (2.5, 5, and 10 Gy) in the presence or absence of IL-4. As expected,  $\gamma$ -irradiation caused a significant decrease in colony numbers (expressed as relative survival fraction) (Figure 4A). However, there was no significant difference in clonogenic recovery between PCa cells co-cultured with STO-IL4 (IC50  $3.44 \pm 1.60$  Gy) and the STO-GUS control (IC50  $5.01 \pm 0.47$  Gy).

To further corroborate whether IL-4 is able to affect the clonogenic recovery rate in response to a treatment, we repeated the assays after exposure to docetaxel, a standard of care chemotherapeutic intervention for CRPC. A significant change in primary cell viability after 72 hours treatment with increasing doses of docetaxel was observed (Supplementary Figure 5A). However, morphological observations (increase in nuclear size) and cell cycle analysis ( $G_2$  arrest) revealed that docetaxel was already effective at the lowest concentration (1.25 nM) tested after 24 hours treatment (Supplementary Figure 5B-E). Subsequently, to investigate whether IL-4 may be involved in relapse after docetaxel treatment, clonogenic recovery assays were performed following an initial 48 hour-treatment with a concentration range from 1.25 nM to 1.25  $\mu$ M docetaxel. Again as expected, a significant decrease in the number of colonies was observed after docetaxel treatment (Figure 4B). Similar to irradiation, no significant changes in either recovery potential or the IC50 between docetaxel-treated cells co-cultured with STO-IL4 (IC50  $1.34 \pm 0.24$  nM) and co-cultured with STO-GUS (IC50  $1.16 \pm 0.06$  nM) could be observed (Figure 4B). We concluded that IL-4 signalling is not able to decrease the sensitivity of primary PCa cells in response to irradiation or docetaxel treatment.

#### **IL-4 treatment induces phosphorylation of STAT6 in PCa cells**



Next, we assessed which downstream signalling pathways are activated by IL-4 and may be involved in the increase in clonogenic potential observed in primary PCa cells. To this end, a Proteome Profiler Human Phospho-Kinase Array was utilised. Four primary PCa cell cultures from different patients were treated for either 30 minutes or 48 hours with 48 hour-conditioned media from STO-IL4 cells. The array revealed that IL-4 treatment triggered a highly heterogeneous response in primary PCa cells, with only phosphorylation of Signal Transducer and Activator of Transcription (STAT) 6 identified as being significantly up-regulated ( $P < 0.05$ ) in all samples and at all time points (Table 1, Figure 5A-C). Activation of STAT6 was validated by Western Blot after treatment with IL-4-containing supernatant from STO-IL4 for either 30 minutes or 48 hours (Figure 5D).

Previous immunohistological studies have reported that STAT6 is over-expressed in PCa (30), and assessment of our TMA for STAT6 expression supported these results (Supplementary Figure 6). However, the data also showed a slight, statistically not significant decrease of both STAT6 mRNA (Figure 5E) and protein (Figure 5F) levels in cancer-derived primary cells compared to benign cells. Cancerous primary cells showed similar STAT6 protein expression to PC3 cells, despite the malignant cells demonstrating higher transcript expression. In contrast, LNCaP cells showed very low STAT6 mRNA expression and no detectable protein (Figure 5E-G). In addition, no differences in STAT6 mRNA levels were observed between the fractionated subpopulations from cancer or benign cultures (Figure 5H). We concluded that STAT6 is highly expressed in primary PCa cells, albeit at lower levels than in benign cells, and can readily be activated by IL-4.

#### **Inhibition of phosphoSTAT6 reverses the IL-4 mediated increase in clonogenic potential**

In order to investigate whether direct inhibition of STAT6 signalling can antagonize the effects of IL-4 on the clonogenic potential of primary PCa cells, a selective STAT6 inhibitor (AS1517499) was used at varying concentrations (31). After toxicity testing in primary cells (Figure 6A), two concentrations of the inhibitor (100 nM and 300 nM) were selected for further use, and their efficacy was verified by Western Blot analysis for STAT6 phosphorylation following IL-4 exposure. Whilst the inhibitor had no observable effect on cell viability (Figure 6A) and total STAT6 protein expression (Figure 6 B+D), the levels of phosphorylated STAT6 decreased to 60% and 20% of initial expression levels following treatment with 100 nM and 300 nM AS1517499, respectively (Figure 6B+C).

As shown in Figure 2B, IL-4 increased the clonogenic potential of primary cancer cells. When PCa cells were co-cultured with STO-IL4 in the presence of 100 nM of AS1517499, this increase in clonogenic potential was

found to be significantly inhibited ( $P < 0.05$ ), (Figure 6E). Furthermore, the higher dose of AS1517499 (300 nM) showed an almost complete reversion of IL-4-increased clonogenic potential, to levels comparable to control (STO-GUS). Although, 300 nM AS1517499 had a minor effect on clonogenic potential of the STO-GUS co-cultured PCa cells, we concluded that the increase of the clonogenic potential of primary PCa cells in response to IL-4 is indeed mediated by STAT6 activation.

## Discussion

The role of important pro-inflammatory cytokines such as IL-1 and IL-6 in carcinogenesis has been extensively investigated (15, 32). In contrast, less is known on the effects, of anti-inflammatory cytokines such as IL-4 on PCa cells. IL-4 is a pleiotropic cytokine produced by a subset of CD4<sup>+</sup> T cells in response to receptor-mediated activation events. It induces a variety of responses in hematopoietic tissues, signalling mainly through the IL4R $\alpha$  subunit, which is present in many tissue types including hematopoietic, endothelial, epithelial, muscle, fibroblast, hepatocyte, and brain (33-35). Using a TMA we were able to demonstrate that IL4R $\alpha$  is significantly overexpressed in luminal PCa cells compared to cells from benign areas of the human prostate. Similar results have been observed in PCa xenograft models where IL4R $\alpha$  is overexpressed in both androgen-dependent and independent tumours (36). These results added PCa to the group of solid human tumours where IL4R $\alpha$  is highly expressed, similar to breast, ovarian and colon cancers (37, 38). Interestingly, we found no significant difference in IL4R $\alpha$  expression between benign and malignant primary basal prostate cells. However, fractionation of these rare cell populations revealed that stem-like cells isolated from cancers have significantly higher expression levels of IL4R $\alpha$ , suggesting a potential tumorigenic role for IL4/IL4R $\alpha$  in PCa CSCs. Previously, IL-4/IL4R $\alpha$  signalling activation was shown to promote clonogenic potential and metastatic colonization in stem-like cells from human colon and mammary cancers (38-40). Similar to these findings, we showed that IL-4 significantly increased the clonogenic potential of PCa primary cells.

Former studies have demonstrated that IL-4 can induce NF- $\kappa$ B activation through activation of PI3K/AKT in PCa cell lines (23). In contrast, we found that IL-4 treatment induced only STAT6 phosphorylation in all the patient-derived cell cultures analysed (despite high heterogeneity between samples). This is supported by the findings of Ni et al, who also showed significant levels of activated STAT6 in primary prostate tissues (41).

Here we describe a new role for IL-4 activated STAT6 in the regulation of clonogenic potential of primary PCa cells. Previous studies from our laboratory have revealed that only the progenitor subpopulations within primary benign and malignant cell cultures hold the ability to form colonies from single cells (12, 13, 42). This observation, combined with our results, leads to the hypothesis that IL-4 directly influences the CSC population by providing a micro-environmental stimulus to exit quiescence and initiate the formation of new colonies from a single cell. This adaptation to the IL-4 producing tumour microenvironment may play a critical role in the promotion of novel tumour-initiating foci, and possibly tumour-initiation at distant sites. This hypothesis is supported by previous findings, which have demonstrated that (i) knock down of STAT6 expression can inhibit tumour metastasis in PCa, (ii) STAT6<sup>-/-</sup> mice are resistant to metastatic disease, and

(iii) STAT6 phosphorylation promotes metastatic potential in colon cancer cells (43-45). However, epithelial to mesenchymal transition (EMT) has also been linked to increased clonogenicity, and may play a role in the observed results (46).

*In vitro* and *in vivo* studies with the STAT6 inhibitor Leflunomide have reported reduced growth and promotion of apoptosis in PCa (47). However, Leflunomide is known to have nonspecific effects and can alter targets other than STAT6 (30, 48, 49). Recently, Nagashima and colleagues synthesized the potent and selective STAT6 inhibitor AS1517499, which has been utilised in this study (49). However, AS1517499 did not reduce proliferation as has been reported for Leflunomide. Despite this, we showed that AS1517499 was able to prevent the IL-4 activated STAT6 increase of the clonogenic potential of primary PCa cells. Moreover, at a dose of 300 nM, AS1517499 decreased the clonogenic potential of primary basal PCa cells. Even though dose-dependent nonspecific effects of AS1517499 cannot be excluded, it is more likely that the reduced clonogenic potential observed is due to the inhibition of basal STAT6 activation, which has been reported previously (41). These results support the hypothetical novel role of STAT6 in the regulation of the clonogenic potential of PCa.

Several markers have been identified in order to isolate the highly tumourigenic CSC from PCa cell lines, as well as primary PCa cells (50). However, these studies differ in both detection methods and the cell culture conditions for the CSC population, which has been shown to be highly adaptive to the microenvironment (51). The model used here was first introduced by Collins and colleagues in 1998, and the laboratory of Maitland and Collins has since then demonstrated the reliability of this model in several publications (7). Others have recently published similar data on primary prostate cells, using the basal cell marker CD49f. In contrast to Witte et al., (8, 50) our data showed that all subpopulations isolated from our primary cells expressed the same levels of CD49f, in agreement with Taylor et al. (7, 9) and Collins et al. (12) who also demonstrated CD49f expression on all the cell subpopulations previously described by Collins and Maitland (12, 13, 28). This implies that, despite the use of different basal cell markers, both groups are ultimately describing the same populations of prostate epithelial cells.

Cytokines play an important role in the development of therapy resistance (52, 53). Current therapies such as radiation and docetaxel can trigger an inflammatory response, and an increase of cytokine levels of IL-6, IL-8, and IL-4 have all been reported (15, 20, 29, 54, 55). *In vitro* studies demonstrated that, in cell lines, IL-4 enhances the DNA repair activity triggered by radiation therapy (56). In this study, we observed that IL-4 had no influence on clonogenic recovery of primary PCa cells following irradiation. Similarly, IL-4 also

demonstrated no influence on the clonogenic recovery potential of primary PCa cells following docetaxel treatment. We therefore conclude that IL-4 does not have a direct influence on therapy resistance in PCa. Here we demonstrate for the first time that activation of STAT6 by IL-4 from the local microenvironment results in a significant increase in the colony forming ability of primary PCa cells. This finding describes a novel role of the IL-4/IL4R $\alpha$ /STAT6 axis in the highly tumorigenic progenitor population of PCa. However, the specific role of STAT6 in rare CSCs has to be clarified in further studies, in order to investigate STAT6 as a potential novel therapeutic target. We have also further demonstrated the complexity of PCa tumour initiation and progression, which highlights the importance of targeting not only the epithelial cell populations but also the tumour microenvironment.

## **Materials and Methods**

### **Culture of cell lines and primary prostate cells**

The PCa cell lines LNCaP, PC3, and Du-145 were obtained from the American Type Culture Collection (Rockville, MD, USA) cultured, and authenticated as previously described (57). The LNCaP sub cell line LNCaP IL-6+ was derived after long-term treatment with IL-6 (58). 293FT cells were cultured as described by Invitrogen (Life Technologies Ltd, Paisley, UK).

Benign and cancerous primary prostate cells were cultured as described previously (6, 13, 28). Tissues were obtained with patients' consent and full ethical approval (Yorkshire and Humber NHS Research Ethics Office - NRES number 07/H1304/121) from patients. Stem cell populations (SC, CD49b<sup>high</sup>/CD133<sup>+</sup>), transit amplifying populations (TA, CD49b<sup>high</sup>/CD133<sup>-</sup>), and committed basal populations (CB, CD44<sup>+</sup>/CD49b<sup>low</sup>/CD133<sup>-</sup>) were obtained via cell fractionation using the protocol previously published by Richardson et al. (28) Patient donor details are listed in Supplementary Table 1.

### **Live cell count**

Collected cells were stained with Trypan Blue (Sigma-Aldrich Company Ltd, Gillingham, UK) and counted using a Neubauer's haemocytometer. Unstained cells were seeded for subsequent experiments.

### **Irradiation of cells**

Cells were irradiated using an RS2000 X-Ray Biological Irradiator, containing a Comet MXR-165 X-Ray Source (Rad-Source Technologies Inc., Suwanee, GA, USA). A dose of 2.5, 5, 10, or 60 Gy was administered with a dose rate of 0.02 or 0.08 Gy s<sup>-1</sup>.

### **STAT6 inhibitor and Docetaxel treatment of cells**

STAT6 inhibitor (AS1517499, Axon Medchem, Groningen, Netherlands) and Docetaxel (Sigma-Aldrich Company Ltd, Gillingham, UK) were dissolved in Dimethyl sulfoxide (DMSO, Sigma-Aldrich Company Ltd, Gillingham, UK). For the STAT6 inhibitor experiments, doses of 10 nM, 30 nM, 100 nM, and 300 nM were used. For Docetaxel experiments, doses of 1.25 nM, 2.5 nM, 5 nM, 10 nM, 100 nM and 1250 nM were used.

### **Cloning strategy of pGLTR-IL-4-PURO and pGLTR-GUS-PURO**

For cloning of human IL-4 cDNA into the lentiviral vector pGLTR-X-PURO, the Invitrogen Gateway Recombination Cloning Technology (Life Technologies Ltd, Paisley, UK) was used. pGLTR-X-PURO was kindly provided by Dr Stephan Geley (59). IL-4 was re-cloned from pcD-human-IL-4(clone 125) (ATCC, Rockville, MD, USA) using a pair of specific primers (5'-CAA AAA AGC AGG CTC CAT GGG TCT CAC CTC CCA AC and 5'-CAA GAA AGC TGG GTC TCA GCT CGA ACA CTT TGA ATA TTTC) which incorporated specific overhangs for the gateway reaction into the pDONOR221. The pDONOR221-*E.coli*- $\beta$ -glucuronidase (GUS) was used for the control vector pGLTR-GUS-PURO and was provided by Invitrogen (Life Technologies Ltd, Paisley, UK).

### **Lentivirus production and generation of stable cell lines**

For production of lentiviral particles, 293FT cells were transfected with psPAX2, pVSV-G, and the corresponding pGLTR-X-PURO expression vector using the calcium phosphate transfection method (60). psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260) and pVSV-G was a gift from Robert Weinberg (Addgene plasmid # 8454) (61). Viral supernatants were harvested 48 hours after transfection and passed through a 0.45  $\mu$ m filter. STO cells were incubated for 8 hours with the virus in the presence of 2  $\mu$ g/ml polybrene and subsequently selected with 5  $\mu$ g/ml puromycin (Sigma-Aldrich Company Ltd, Gillingham, UK).

### **[<sup>3</sup>H] Thymidine incorporation assay and MTT Assay**

PC3, Du145, and LNCaP IL-6+ cell lines were seeded at a density of  $2 \times 10^3$  cells/well and LNCaP cells at  $10 \times 10^3$  cells/well in triplicate onto 96-well plates. On the following day, cells were treated with different concentrations of IL-4 (0; 0.1; 1; 5; 10 ng/ml, Sigma-Aldrich Company Ltd, Gillingham, UK) and were incubated for 96 h.

To measure DNA synthesis, [<sup>3</sup>H] labelled thymidine (1  $\mu$ Ci/well) was added to the wells 12 h before harvesting. The DNA was harvested on UniFilter 96-well filter plates (Perkin-Elmer, Vienna, Austria) and 50  $\mu$ l Scintillation fluid was added. The radioactivity was quantified using a Chameleon 5025 liquid scintillation counter (HVD Life Sciences, Vienna, Austria).

For the MTT Assay the EZ4U Proliferation Assay (Biomedica, Vienna, Austria) was used and performed following the manufacturer's protocol.

### **Western blot Analysis**

For western blot analysis cells were washed with Phosphate-buffered saline (PBS) and lysed in Radioimmunoprecipitation assay (RIPA) buffer supplemented with complete Mini EDTA-free protease inhibitor tablets (Roche, Welwyn Garden City, UK) and the phosphatase inhibitor cocktail PhosSTOP (Roche, Welwyn Garden City, UK). Protein quantification and western blot was performed as described earlier (62). Antibodies used are listed in Supplementary Table 2. For the western blot experiments STO-free cultures were used and treated with 48 h conditioned media from STO-GUS or STO-IL4.

### **Flow cytometry**

Flow cytometry for IL4R $\alpha$  (CD124) was performed as described before by Kroon et al (18). Antibodies used are listed in Supplementary table 2. All experiments were performed in at least 3 independent biological replicates unless otherwise specified

### **Clonogenic and clonogenic recovery assays**

The clonogenic potential and clonogenic recovery assays were performed as previously described (63). 200 cells were plated from semi-confluent primary prostate cells onto 6-well collagen I-coated plates (BD Biocoat; BD Biosciences, San Jose, USA) in the presence of irradiated STO cells. Colonies were counted after 15 days and recorded if they contained more than 32 cells (5 population doublings).

### **Cell migration and invasion assays**

Cell migration and invasion assays were performed as previously described (64). All experiments were performed in at least 3 independent biological replicates unless otherwise specified.

### **Quantitative real-time PCR for mRNA**

Total RNA was extracted from cells using Qiagen RNeasy mini Kit (Qiagen, Manchester, UK) according to the manufacturer's protocol. RNA was reverse transcribed using random hexamers (Life Technologies Ltd, Paisley, UK) and the reverse transcriptase kit SuperScript III (Life Technologies Ltd, Paisley, UK).

Quantitative real-time PCR (qPCR) was conducted using TaqMan gene expression assays (Life Technologies Ltd, Paisley, UK) and the iTaq™ Universal Supermixes (Bio-Rad Laboratories Ltd, Hertfordshire, UK), according to the manufacturer's protocol.

### **Proteome Profiler Human Phospho-Kinase Array**



For the Proteome Profiler Human Phospho-Kinase Array (R&D, Abingdon, UK)  $1 \times 10^6$  primary PCa cells were seeded in a collagen-I coated 10 cm-well plate and treated with 48 h-conditioned media from STO-IL4 or STO-GUS for 30 min or 48 h. The array was performed according to the manufacturer's manual and developed in a GeneGnome XRQ imaging system (Syngene, Cambridge, UK).

### **Tissue microarray and immunohistochemistry**

The construction of the tissue microarray (TMA) for IL4R $\alpha$  was performed as previously described (57). Georg Schäfer evaluated the TMA by using the semiquantitative scoring system "quickscore" by multiplication of the proportion of positive cells and the average staining intensity (65).

### **Statistical Analysis**

Prism 6 (GraphPad Software, La Jolla, CA, USA) was used for statistical analyses and the evaluation of the IC50. Gaussian distribution was determined using Kolmogorov–Smirnov test. Mann–Whitney U or Student's t-test (two-sided) were used to determine whether two sets of data were significantly different from each other. For correlation analysis (Pearson's method) SPSS (IBM United Kingdom Limited, Hampshire, UK) was used. Data is presented as mean $\pm$ standard deviation (SD) or mean $\pm$ standard error of mean (SEM) unless otherwise specified. Mean $\pm$ SD was used to describe the distribution of the sample values in an experiment and SEM was used to estimate how variable the means were in multiple repeated experiments (66). P-values of <0.05 were considered significant. All differences highlighted by asterisks were statistically significant as encoded in figure legends (\*P<0.05; \*\*P<0.01; \*\*\*P<0.001). All experiments were performed in at least 3 independent biological replicates unless otherwise specified.

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgments**

We thank all the urology surgeons M S Simms, L Coombes, G Cooksey and J Hetherington (Castle Hill Hospital, Cottingham, UK). In addition, we want to thank Georg Schäfer for evaluating the TMA. We would also like to thank the patients who kindly provided samples. The Cancer Research Unit, University of York is acknowledged for their support and helpful discussions. This work was funded by PRO-NEST Marie-Curie Grant (238278 to ZC), Forschungsfoerderung der Oesterreichische Krebshilfe Tirol 2012 (to HHHE), and the Austrian Science Fund FWF (P26799 to FRS). Further support for NJM was provided by Charity Soul and Yorkshire Cancer Research (Y257PA).

Supplementary Information accompanies the paper on the Oncogenesis website  
(<http://www.nature.com/oncsis>)

## References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87-108.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. *Eur Urol*. 2014;65(1):124-37.
3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. *European urology*. 2014;65(2):467-79.
4. Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. *Urology*. 2006;68(3):593-8.
5. Rane JK, Pellacani D, Maitland NJ. Advanced prostate cancer--a case for adjuvant differentiation therapy. *Nat Rev Urol*. 2012;9(10):595-602.
6. Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD, et al. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. *British journal of cancer*. 2013;109(12):3023-33.
7. Frame FM, Maitland NJ. Cancer stem cells, models of study and implications of therapy resistance mechanisms. *Advances in experimental medicine and biology*. 2011;720:105-18.
8. Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(47):E6544-52.
9. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Australian Prostate Cancer B, et al. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. *Stem cells*. 2012;30(6):1087-96.
10. Maitland NJ, Frame FM, Polson ES, Lewis JL, Collins AT. Prostate cancer stem cells: do they have a basal or luminal phenotype? *Hormones & cancer*. 2011;2(1):47-61.
11. Polson ES, Lewis JL, Celik H, Mann VM, Stower MJ, Simms MS, et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. *Nature communications*. 2013;4:1623.
12. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. *J Cell Sci*. 2001;114(Pt 21):3865-72.

13. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res.* 2005;65(23):10946-51.
14. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. *Nat Rev Clin Oncol.* 2015;12(10):584-96.
15. Culig Z. Cytokine disbalance in common human cancers. *Biochim Biophys Acta.* 2011;1813(2):308-14.
16. Culig Z, Puhf M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. *Mol Cell Endocrinol.* 2012;360(1-2):52-8.
17. Ishiguro H, Akimoto K, Nagashima Y, Kagawa E, Sasaki T, Sano JY, et al. Coexpression of aPKC $\lambda$ /iota and IL-6 in prostate cancer tissue correlates with biochemical recurrence. *Cancer Sci.* 2011;102(8):1576-81.
18. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. *Cancer Res.* 2013.
19. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. *Annu Rev Immunol.* 1999;17:701-38.
20. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. *J Urol.* 2000;164(3 Pt 1):722-5.
21. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. *Journal of immunology.* 2004;172(9):5467-77.
22. Goldstein R, Hanley C, Morris J, Cahill D, Chandra A, Harper P, et al. Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. *Cancers (Basel).* 2011;3(4):4281-93.
23. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. *Prostate.* 2005;64(2):160-7.
24. Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC. Interleukin-4 activates androgen receptor through CBP/p300. *Prostate.* 2009;69(2):126-32.
25. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. *Prostate.* 2008;68(1):85-91.

26. Roca H, Craig MJ, Ying C, Varsos ZS, Czarnieski P, Alva AS, et al. IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. *Journal of cellular biochemistry*. 2012;113(5):1569-80.
27. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. *J Allergy Clin Immunol*. 2000;105(6 Pt 1):1063-70.
28. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. *J Cell Sci*. 2004;117(Pt 16):3539-45.
29. Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, et al. Interleukin-4 in patients with prostate cancer. *Anticancer Res*. 2005;25(6C):4595-8.
30. Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. *The Prostate*. 2007;67(14):1550-64.
31. Chiba Y, Todoroki M, Misawa M. Interleukin-4 upregulates RhoA protein via an activation of STAT6 in cultured human bronchial smooth muscle cells. *Pharmacological research*. 2010;61(2):188-92.
32. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. *Clin Cancer Res*. 2011;17(19):6125-9.
33. Ohara J, Paul WE. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. *Nature*. 1987;325(6104):537-40.
34. Lowenthal JW, Castle BE, Christiansen J, Schreurs J, Rennick D, Arai N, et al. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. *J Immunol*. 1988;140(2):456-64.
35. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4<sup>+</sup> T cells. *Annu Rev Immunol*. 1994;12:635-73.
36. Husain SR, Kawakami K, Kawakami M, Puri RK. Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models. *Mol Cancer Ther*. 2003;2(3):245-54.
37. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. *Br J Cancer*. 2005;92(5):921-8.
38. Koller FL, Hwang DG, Dozier EA, Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. *Carcinogenesis*. 2010;31(6):1010-7.

39. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell stem cell*. 2007;1(4):389-402.
40. Venmar KT, Carter KJ, Hwang DG, Dozier EA, Fingleton B. IL4 receptor ILR4alpha regulates metastatic colonization by mammary tumors through multiple signaling pathways. *Cancer Res*. 2014;74(16):4329-40.
41. Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR, et al. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. *The Journal of urology*. 2002;167(4):1859-62.
42. Lang SH, Frame FM, Collins AT. Prostate cancer stem cells. *The Journal of pathology*. 2009;217(2):299-306.
43. Wang N, Tao L, Zhong H, Zhao S, Yu Y, Yu B, et al. miR-135b inhibits tumour metastasis in prostate cancer by targeting STAT6. *Oncology letters*. 2016;11(1):543-50.
44. Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. *J Immunol*. 2002;169(10):5796-804.
45. Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Yuan J, et al. IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. *Biochem Biophys Res Commun*. 2008;369(2):554-60.
46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*. 2008;133(4):704-15.
47. Hail N, Jr., Chen P, Bushman LR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. *Neoplasia*. 2010;12(6):464-75.
48. Chiba Y, Todoroki M, Nishida Y, Tanabe M, Misawa M. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. *American journal of respiratory cell and molecular biology*. 2009;41(5):516-24.
49. Nagashima S, Yokota M, Nakai E, Kuromitsu S, Ohga K, Takeuchi M, et al. Synthesis and evaluation of 2-[[2-(4-hydroxyphenyl)-ethyl]amino]pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. *Bioorganic & medicinal chemistry*. 2007;15(2):1044-55.
50. Santer FR, Erb HH, McNeill RV. Therapy escape mechanisms in the malignant prostate. *Seminars in cancer biology*. 2015;35:133-44.

51. Michael S, Achilleos C, Panayiotou T, Strati K. Inflammation Shapes Stem Cells and Stemness during Infection and Beyond. *Frontiers in cell and developmental biology*. 2016;4:118.
52. Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. *Biochimica et biophysica acta*. 2016;1865(2):255-65.
53. Laine A, Iyengar P, Pandita TK. The role of inflammatory pathways in cancer-associated cachexia and radiation resistance. *Molecular cancer research : MCR*. 2013;11(9):967-72.
54. Di Maggio FM, Minafra L, Forte GI, Cammarata FP, Lio D, Messa C, et al. Portrait of inflammatory response to ionizing radiation treatment. *Journal of inflammation*. 2015;12:14.
55. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. *OncoTargets and therapy*. 2014;7:1015-23.
56. Ciszewski WM, Wagner W, Kania KD, Dastych J. Interleukin-4 enhances PARP-dependent DNA repair activity in vitro. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research*. 2014;34(9):734-40.
57. Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, et al. IL6 sensitizes prostate cancer to the antiproliferative effect of IFNalpha2 through IRF9. *Endocrine-related cancer*. 2013;20(5):677-89.
58. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. *Clin Cancer Res*. 2001;7(9):2941-8.
59. Sigl R, Ploner C, Shivalingaiah G, Kofler R, Geley S. Development of a multipurpose GATEWAY-based lentiviral tetracycline-regulated conditional RNAi system (GLTR). *PLoS One*. 2014;9(5):e97764.
60. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. *Nature protocols*. 2009;4(4):495-505.
61. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. *RNA*. 2003;9(4):493-501.
62. Rane JK, Erb HH, Nappo G, Mann VM, Simms MS, Collins AT, et al. Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. *Oncotarget*. 2016.
63. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. *Nat Protoc*. 2006;1(5):2315-9.



64. Puhr M, Hofer J, Schafer G, Erb HH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. *Am J Pathol.* 2012;181(6):2188-201.
65. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. *Journal of clinical pathology.* 1995;48(9):876-8.
66. Vaux DL. Research methods: Know when your numbers are significant. *Nature.* 2012;492(7428):180-1.

## Figure Legends

### Figure 1: IL4R $\alpha$ expression in prostate epithelial cells

(A) Immunohistochemical staining for IL4R $\alpha$  of representative malignant tissue and adjacent benign tissue cores from a PCa patient. Scale bar = 200  $\mu$ M

(B) Evaluation of a TMA of malignant tissue and adjacent benign tissue cores from PCa patients (n=36) stained for expression of IL4R $\alpha$ . Data is shown as Box and whisker diagrams (10 % to 90 %, \*\*\*: p<0.001, Outliers are shown as dots)

(C) IL4R $\alpha$  mRNA levels in LNCaP (n=3), PC3 (n=3), benign (n=8) and malignant (n=8) primary prostate cell cultures normalised to RPLP0 expression. Data is shown as Box and whisker diagrams (min to max; n.s.: not significant; \*: p<0.05).

(D) IL4R $\alpha$  protein levels of LNCaP (n=3), PC3 (n=3), benign (n=4), and malignant (n=5) primary prostate cell cultures analysed by flow cytometry. Data is shown as Box and whisker diagrams (min to max; n.s.: not significant; \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001).

(E) IL4R $\alpha$  mRNA levels of individual cell subpopulations from benign and malignant primary prostate cell cultures (n=6). Data is shown as Box and whisker diagrams (min to max; n.s.: not significant; \*: p<0.05).

Abbreviations: IL4R $\alpha$  = IL-4 receptor alpha, SC = tissue stem cell, CSC = cancer stem cell, TA = transit amplifying, CTA = cancer transit amplifying, CB = committed basal, CCB = cancer committed basal.

### Figure 2: IL-4 increases clonogenic potential of primary PCa cells

(A) Clonogenic assays of benign primary prostate cells (n=4) co-cultured with STO-GUS or STO-IL4 feeder cells. The number of colonies ( $\geq$ 32 cells) was scored 15 days after plating. The results are expressed as fold change in the number of colonies and are normalised to the STO-GUS control. A representative crystal violet staining is shown at day 15. Data is shown as mean $\pm$ S.D. (n.s.: not significant; \*: p<0.05).

(B) Clonogenic assays of malignant primary prostate cells (n=4) co-cultured with STO-GUS or STO-IL4 feeder cells. The number of colonies (>32 cells) was scored 15 days after plating. The results are expressed as fold change in the number of colonies and are normalised to the STO-GUS control. A representative crystal violet staining is shown at day 15. Data is shown as mean $\pm$ S.D. (\*: p<0.05).

(C) Average colony growth of benign primary prostate cells (n=3) co-cultured with STO-GUS or STO-IL4 feeder cells. Cell numbers from 2 colonies from each condition was counted at day 8 and 15 and the increase in cell number of one colony expressed as fold change. Data is shown as mean $\pm$ S.D. (n.s.: not significant).

(D) Average colony growth of malignant primary prostate cells (n=3) co-cultured with STO-GUS or STO-IL4 feeder cells. Cell numbers from 2 colonies from each well were counted at day 8 and 15 and the colony growth expressed as fold change. Data is shown as mean±S.D (n.s.: not significant).

(E) Time course of colony formation ( $\geq 32$  cells) in primary PCa cell cultures (n=3) co-cultured with STO-IL4 or STO-GUS for 8 days. The results are expressed as total number of colonies. Data is shown as mean±SEM (\*: p<0.05).

(F) Clonogenic assay of primary PCa cells (n=3) co-cultured with a combination of STO-GUS and STO-IL4 feeder cells in different ratios (1:1-1:10000). The number of colonies ( $\geq 32$  cells) was scored 15 days after plating. The results are expressed as total number of colonies. Data is shown as mean±SEM (\*: p<0.05).

### **Figure 3: IL-4 does not influence the migration or invasion potential of primary PCa cells**

(A) Fold change in migration of primary cancer cells after 24 hours and 48 hours incubation compared to controls (n=4). KSFM without added supplements served as a negative control for migration (nCTRL 0% FCS). KSFM supplemented with 30% FCS served as positive control (pCTRL 30% FCS; \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001).

(B) Fold change in invasion through matrigel of primary PCa cells after 24 hours and 48 hours incubation compared to controls (n=4). KSFM without added supplements served as a negative control for invasion (nCTRL 0% FCS). KSFM supplemented with 30% FCS served as positive control (pCTRL 30% FCS; \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001).

Abbreviations: nCTRL = negative Control, pCTRL = positive Control.

### **Figure 4: IL-4 does not influence the recovery potential of primary PCa after irradiation or docetaxel treatment**

(A) Clonogenic recovery assay of primary PCa cells (n=3) co-cultured with STO-GUS or STO-IL4 feeder cells after irradiation with 0, 2.5, 5 and 10 Gy. The number of colonies ( $\geq 32$  cells) was scored 10 days after plating. The results are expressed as % survival decrease in the number of colonies and normalised to no radiation (0 Gy) control. IC50 was calculated with Graph Pad Prism from these results (n.s.: not significant).

(B) Clonogenic recovery assay of primary PCa cells (n=3) co-cultured with STO-GUS or STO-IL4 feeder cells after 48 h treatment with different doses of docetaxel (0, 1.25, 2.5, 5, 10, 100 and 1250 nM). The number of colonies ( $> 32$  cells) was scored 10 days after plating. The results are expressed as % survival

decrease in the number of colonies and normalised to no treated (0 nM) control (n=3). IC50 was calculated with Graph Pad Prism from these results (n.s.: not significant).

**Figure 5: IL-4 treatment induces phosphorylation of STAT6 in PCa**

(A) Representative membranes from the Human Phospho-Kinase Antibody Array. Samples were treated with 48 hours-conditioned media from either STO-GUS controls (first lane) or STO-IL4, for either 30 minutes (second lane) or 48 hours (third lane). Red rectangle=STAT6.

(B) Highlighted pSTAT6 dots on the representative membranes from the Human Phospho-Kinase Antibody Array.

(C) Fold change of pSTAT6 after 30 minutes and 48 hours of IL-4 exposure in the Human Phospho-Kinase Antibody Array compared to the untreated control (n=4 PCa). Data is shown as mean±S.D. (\*: p<0.05 \*\*: p<0.01). A 2-fold change was chosen as the threshold for up-regulation (black line).

(D) Validation for pSTAT6 by Western Blot analysis of primary PCa cells treated with conditioned media from STO-GUS and STO-IL4 for 30 minutes or 48 hours (n=1).

(E) mRNA levels of STAT6 in LNCaP (n=3) and PC3 (n=3) cell lines, and benign (n=8) and malignant (n=8) primary prostate cell cultures. Data is shown as Box and whisker diagrams (min to max; n.s.: not significant; \*: p<0.05).

(F) Representative Western Blot for STAT6 from primary prostate benign cells (n=3), primary PCa cells (n=3), PC3 (n=1) and LNCaP (n=1) cell lines. PC3 cells were used as a positive control and LNCaP cells as a negative control.

(G) Protein levels of STAT6 analysed in primary prostate benign (n=3) and cancer cells (n=3) from the representative Western Blot (Figure 5F). PC3 cells were used as a positive control and LNCaP cells as a negative control. Data is shown as Box and whisker diagrams (min to max; n.s.: not significant; \*: p<0.05).

(H) mRNA levels of STAT6 in individual cell subpopulations from benign and malignant prostate biopsies (n=4). Data is shown as Box and whisker diagrams (min to max; n.s.: not significant).

Abbreviations: SC = tissue stem cell, CSC = cancer stem cell, TA = transit amplifying, CTA = cancer transit amplifying, CB = committed basal, CCB = cancer committed basal.

**Figure 6: Inhibition of phosphoSTAT6 reverses the IL-4 mediated effects on clonogenic potential**

(A) Cell viability of primary PCa cells treated with different doses of AS1517499 for 24, 48 and 72 hours using the Alamar Blue assay (n=3; n.s.: not significant).

(B) Two representative western blots of phosphorylated and total STAT6 in primary PCa cells exposed to two different (100 nm, 300 nm) doses of AS1517499 combined with STO-IL4 supernatant for 30 minutes.

(C) Densitometry analysis of pSTAT6 expression in AS1517499/IL-4 treated primary PCa cells compared to untreated controls (n=3; \*:  $p<0.05$  \*\*:  $p<0.01$ ).


(D) Densitometry analysis of total STAT6 protein expression in AS1517499/IL-4 treated primary PCa cells compared to untreated controls (n=3; n.s.: not significant).

(E) Fold change in the number of colonies in primary benign and cancer prostate cells after 15 days of culture with two doses of AS1517499 (n=3 benign, n=3 cancer). (\*:  $P<0.05$ ; \*\*:  $P<0.01$ ; \*\*\*:  $P<0.001$ ).

**Table 1: Evaluation of the Human Phospho-Kinase Antibody Array after treatment of primary PCa cells with IL-4**


X-fold change in phosphorylation status in primary PCa cells after treatment for 30 min 48 h with conditioned media from STO-IL4. The results of the Human Phospho-Kinase Antibody Array were evaluated from densitometry analysis of the spotted membrane normalised to the untreated control (STO-GUS conditioned media). Red= upregulation, green= downregulation (n=4 PCa). Red rectangle= pSTAT6

Figure 1: IL4R $\alpha$  expression in prostate epithelial cells





(n.s.: not significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ )

Figure 2: IL-4 increases clonogenic potential of primary PCa cells




48 h



(\*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001)



Figure 4: IL-4 does not influence the recovery potential of primary PCa after irradiation or docetaxel treatment



(n.s.: not significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ )

Figure 5: IL-4 treatment induces phosphorylation of STAT6 in prostate cancer





Figure 6: Inhibition of STAT6 reverses the IL-4 mediated effects on clonogenic potential



(n.s.: not significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ )

STOs IL-4	30 min					48 h				
SAMPLE	H116/11	H043/11	H039/11	H265/12	p-value	H116/11	H043/11	H039/11	H265/12	p-value
Akt (S473)	1.19	0.70	1.08	0.68	0.551	1.06	2.16	0.59	1.18	0.509
Akt (T308)	0.43	0.96	0.89	1.01	0.280	1.58	0.39	0.84	2.31	0.554
AMPK alpha1 (T174)	1.45	0.43	0.56	0.33	0.317	1.92	0.78	0.88	1.39	0.424
AMPK alpha2 (T172)	6.16	1.08	1.21	1.14	0.346	4.59	0.94	0.78	2.68	0.256
beta-Catenin	26.63	0.97	0.18	1.24	0.404	33.37	1.26	0.59	2.44	0.370
Chk-2 (T68)	4.79	1.00	0.74	0.50	0.511	3.80	1.13	0.68	1.50	0.345
c-Jun (S63)	7.41	0.40	0.89	0.89	0.465	16.17	0.55	1.67	1.56	0.364
CREB (S133)	18.17	0.62	0.62	0.39	0.436	7.21	1.89	0.71	1.22	0.327
EGF R (Y1086)	5.24	0.82	0.61	0.90	0.484	2.29	1.97	0.53	1.66	0.208
eNOS (S1177)	0.08	0.78	1.12	0.09	0.159	0.46	0.46	0.98	1.61	0.684
ERK1/2 (T202/Y204, T185/Y187)	0.58	0.84	1.53	0.87	0.839	0.48	0.80	0.64	2.56	0.820
FAK (Y397)	10.83	1.27	1.09	0.31	0.411	5.85	1.48	0.66	0.34	0.459
Fgr (Y412)	7.19	4.87	1.08	1.00	0.193	0.68	2.37	0.72	1.19	0.588
Fyn (Y420)	2.32	1.59	0.83	0.99	0.289	0.00	3.48	0.61	1.96	0.556
GSK-3 alpha/beta (S21/S9)	1.14	0.46	0.77	0.79	0.231	1.38	1.56	0.66	1.75	0.250
Hck (Y411)	0.55	0.74	0.70	0.80	0.010	0.95	0.57	0.61	1.83	0.974
HSP27 (S78/S82)	5.19	1.83	1.50	0.95	0.250	4.88	2.99	0.79	0.74	0.267
HSP60	0.00	0.65	0.23	0.01	0.014	0.00	0.41	0.67	1.21	0.189
JNK pan (T183/Y185, T221/Y223)	1.60	0.92	0.85	0.99	0.646	3.64	1.79	0.98	1.81	0.157
Lck (Y394)	0.00	3.00	1.01	0.98	0.719	2.24	1.46	0.73	2.31	0.162
Lyn (Y397)	1.57	3.74	0.94	1.22	0.266	0.01	2.36	0.57	2.68	0.581
MSK1/2 (S376/S360)	0.94	1.28	1.24	1.25	0.116	1.30	1.33	0.94	1.57	0.115
p27 (T198)	0.31	0.23	0.90	7.50	0.535	0.00	0.06	0.62	13.36	0.501
p38 alpha (T180/Y182)	0.99	1.18	0.71	0.88	0.587	1.75	2.08	1.00	2.04	0.065
p53 (S15)	112.54	0.78	0.65	0.69	0.395	92.80	0.54	0.83	5.44	0.369
p53 (S392)	546.11	0.36	0.42	0.68	0.393	899.86	0.52	0.75	2.02	0.391
p53 (S46)	1.50	0.73	0.80	1.50	0.571	5.30	0.28	0.85	2.61	0.346
p70 S6 Kinase (T389)	0.00	0.47	0.84	1.04	0.167	0.00	0.31	1.03	3.28	0.848
p70 S6 Kinase (T421/S424)	1.19	0.49	0.74	1.52	0.959	1.83	0.31	0.89	4.64	0.410
PDGF R beta (Y751)	0.48	3.68	0.97	0.61	0.605	2.98	2.18	0.74	1.67	0.153
PLC gamma-1 (Y783)	0.00	0.70	1.19	0.11	0.167	8.62	0.51	1.00	3.97	0.269
PRAS40 (T246)	4.02	0.93	1.22	0.87	0.389	0.31	1.17	0.87	1.42	0.823
Pyk2 (Y402)	0.06	0.72	1.08	0.83	0.225	0.47	0.42	0.83	1.54	0.528
RSK1/2/3 (S380/S386/S377)	0.00	0.65	0.97	2.01	0.843	0.00	0.33	0.79	6.97	0.581
Src (Y419)	0.00	1.02	1.05	1.14	0.510	1.84	1.08	0.76	1.71	0.269
STAT2 (Y689)	1.69	2.67	1.16	0.67	0.290	2.11	2.15	0.92	2.05	0.073
STAT3 (S727)	1.85	0.35	1.08	0.40	0.836	23.90	0.07	0.87	2.01	0.393
STAT3 (Y705)	5.35	0.85	1.06	18.18	0.280	11.47	0.34	0.91	64.60	0.317
STAT5a (Y694)	1.81	1.53	1.02	1.36	0.079	2.22	0.92	0.75	2.42	0.275
STAT5a/b (Y694/Y699)	3.63	1.49	1.08	1.26	0.242	0.53	1.12	0.70	2.14	0.752
STAT5b (Y699)	4.41	1.85	1.12	1.19	0.236	1.84	2.17	0.77	1.88	0.118
STAT6 (Y641)	2.83	4.54	2.90	1.75	0.040	3.02	10.33	2.18	3.52	0.046
TOR (S2448)	36.98	1.66	0.81	1.04	0.383	1.10	1.71	0.62	1.79	0.353
WNK-1 (T60)	27.05	0.61	0.35	0.05	0.434	8.21	0.22	0.40	0.85	0.516
Yes (Y426)	4.63	2.45	1.10	1.18	0.204	0.85	1.45	0.79	1.82	0.427